Skip to Main content Skip to Navigation
New interface
Journal articles

SARS-CoV-2 vaccination in IBD: more pros than cons

Abstract : Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.
Document type :
Journal articles
Complete list of metadata
Contributor : Djésia Arnone Connect in order to contact the contributor
Submitted on : Tuesday, November 9, 2021 - 4:12:17 PM
Last modification on : Thursday, January 20, 2022 - 3:09:04 PM

Intranet access




Ferdinando D’amico, Christian Rabaud, Laurent Peyrin-Biroulet, Silvio Danese. SARS-CoV-2 vaccination in IBD: more pros than cons. Nature reviews. Gastroenterology & hepatology, 2021, 18 (4), pp.211-213. ⟨10.1038/s41575-021-00420-w⟩. ⟨hal-03421547⟩



Record views